Daniel Janney, Director at Krystal Biotech, Inc. (KRYS), sold 11,803 shares at $276.17 ($3.3M) on 2026-02-27, disclosed to the SEC on 2026-03-03.
Scheduled sale ($3.3M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $275.45 | 9,430 | $2.6M | 79.9% |
| 2 | $276.17 | 2,373 | $655K | 20.1% |
| Total | $275.59 avg | 11,803 | $3.3M | 100% |
| Filing → |
| KRYS | SELL | 2023-05-23 | $4.8M | — | Filing → |
| KRYS | SELL | 2023-05-11 | $1.6M | — | Filing → |
| KRYS | SELL | 2023-04-21 | $714K | — | Filing → |